抗代谢药物

  • 网络antimetabolite
抗代谢药物抗代谢药物
  1. 抗青光眼滤过手术中抗代谢药物促滤泡形成的临床研究

    Clinical study of promoting filtration bleb with antimetabolites on glaucoma filtering surgery

  2. 由于PVR的手术治疗效果仍不理想,许多学者已经研究了多种药物防治PVR,包括抗代谢药物、皮质类固醇药物、维生素类药物、钙通道阻滞剂以及基因治疗等。

    Effects of surgical therapy are not ideal . Parmaceutical studies have been developed , including antimetabolite , corticosteroid , nutramines , calcium-channel blockers , gene therapy and so on .

  3. 几种代谢和抗代谢药物对λDNA的遗传毒性分析

    Analysis of genetic toxicity of several metabolic and anti-metabolic chemicals to λ DNA

  4. Nd∶YAG激光联合抗代谢药物治疗阻塞性泪道疾病

    The Clinical Result of Nd ∶ YAG Laser Combined with Mitomycin C in Treating Obstructive Disease of The Lacrimal Duct

  5. 目的:探讨抗代谢药物丝裂霉素C(mitomycinC,MMC)对实验性椎板切除术后硬膜外瘢痕组织中羟脯氨酸(HOP)含量的影响。

    Objective : To study the effect of mitomycin C , an anti-metabolic drug , on content of Hydroxyproline in the epidural scar tissue of experimental post-laminectomy .

  6. 用来治疗某种癌症的抗代谢药物。

    An antimetabolite used to treat certain cancers .

  7. 因此,目前提高青光眼滤过手术成功率的主要手段之一就是植入物与抗代谢药物的结合。

    Thus , one focus of the glaucoma filtering surgery is the combination of antimetabolite and implantation .

  8. 吉西他滨是一种周期特异性抗代谢药物,临床主要用于非小细胞肺癌、胰腺癌、膀胱癌、乳腺癌及其他实体肿瘤的治疗。

    Gemcitabine is a cell cycle specific anticancer agent that are effective for therapy of non-small cell lung cancer ( NSCLC ), breast cancer , ovarian cancer and pancreatic carcinoma and other solid cancers .

  9. 结论服用6MP前测定TPMT活性和服药时监测TGNs浓度能够有助于预防抗嘌呤代谢药物的不良反应,指导其化疗个体化,改善疗效。

    Conclusion Detection of TPMT activity before 6-MP therapy and TGNs level during 6-MP therapy may be helpful for preventing side effects from antipurine metabolic drug overdose , and individualizing 6-MP chemotherapy in children with ALL .

  10. 传统的化疗药物主要有抗代谢类药物、烷化剂类、抗生素类、铂类和植物类等5大类药物。

    Traditional chemotherapy medicine has five kinds , including anti-metabolism , alkylating agent , antibiotics , platinum and plants .

  11. 这一现象为设计各种抗肿瘤代谢的药物提供了生物化学基础。

    It provides a biochemical basis for the design of the anti-metabolic agents for cancer treatment .